Firebrick Pharma (ASX:FRE) has signed a license and distribution agreement with Fiji Islands company Makans, under which Makans will immediately start to promote and sell the Nasodine nasal spray in Fiji and South Pacific, the company said in a Wednesday Australian bourse filing.
Under the deal, Makans will pay the company a manufacturing/handling fee equivalent to 20% of the cost of goods of licensed products supplied by the company and also a fee of AU$1.80 per unit of licensed products sold.
The Company expects an initial order from Makans of approximately 1,000 units of Nasodine, the filing said.
The agreement is for an initial term of one year renewable for successive one-year terms, the filing added.
Company shares were down 4% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。